Targeted Delivery of Cabazitaxel Using Cyclic Cell-Penetrating Peptide and Biomarkers of Extracellular Matrix for Prostate and Breast Cancer Therapy.
Amino Acid Sequence
Antineoplastic Agents
/ administration & dosage
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell-Penetrating Peptides
/ chemistry
Drug Delivery Systems
Female
HEK293 Cells
Humans
Male
Molecular Structure
Prostatic Neoplasms
/ drug therapy
Taxoids
/ administration & dosage
Journal
Bioconjugate chemistry
ISSN: 1520-4812
Titre abrégé: Bioconjug Chem
Pays: United States
ID NLM: 9010319
Informations de publication
Date de publication:
18 08 2021
18 08 2021
Historique:
pubmed:
27
7
2021
medline:
15
12
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Targeted drug delivery for cancer therapy is an emerging area of research. Cancer cells overexpress certain biomarkers that can be exploited for their targeted therapy. Cyclic cell-penetrating peptides (cCPP) are increasingly assessed for intracellular cargo delivery in cancer cells. In this study, we have conjugated cabazitaxel (CBT) to the cCPP via an ester bond to assist CBT release in the tumor's acidic environment. Integrin targeting (RGDC, TP1) and extra domain B of fibronectin (EDB-Fn) targeting (CTVRTSAD, TP2) peptides were linked to the peptide-drug conjugate (cCPP-CBT) via a disulfide bond to provide targeting ability to the conjugates until they reach the tumor site. Conjugate
Identifiants
pubmed: 34309357
doi: 10.1021/acs.bioconjchem.1c00319
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Cell-Penetrating Peptides
0
Taxoids
0
cabazitaxel
51F690397J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM